Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE Pioglitazone is one of the thiazolidinediones (TZDs) drugs that are selective peroxisome proliferator-activated receptor (PPAR-γ agonists used for treating type 2 diabetes mellitus (T2DM). 31709631 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE PPARα agonists (fibrates) and PPARγ agonists (thiazolidinediones) are used for the treatment of hypertriglyceridemia and type 2 diabetes, respectively. 31825687 2020
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE This review discusses the physiological and metabolic actions of GH on adipose tissue as well as GH-mediated deregulation of the FSP27-PPARγ axis which alters adipose tissue homeostasis and contributes to the development of insulin resistance and Type 2 diabetes. 31599132 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE Background Previous genome-wide association studies (GWAS) identified IGF1, IRS1, GCKR, PPARG, GCK1 and KCTD1 as candidate genes for insulin resistance and type 2 diabetes (T2D). 30864372 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE Peroxisome proliferator-activated receptor γ (PPARγ) is a major therapeutic target for the treatment of type 2 diabetes. 31371757 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 AlteredExpression disease BEFREE Thiazolidinedione drugs (TZDs) target the transcriptional activity of peroxisome proliferator activated receptor γ (PPARγ) to reverse insulin resistance in type 2 diabetes, but side effects limit their clinical use. 30639037 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 GeneticVariation disease GWASCAT Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population. 30718926 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR. 30594432 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE Oxadiazolyl thiazolidinedione as a non-adipogenic PPAR-γ partial agonist and its effect on glucose homeostasis in type 2 diabetes. 31204468 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE PPARγ is involved in glucose metabolism and is a potential therapeutic target in Type 2 diabetes. 30827999 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE Furthermore, glitazones, the synthetic thiazolidinediones, also known as insulin sensitizers, are the largely studied PPARγ agonists and the only ones approved for the treatment of type 2 diabetes. 31131751 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE Pioglitazone is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist and is widely used to treat type 2 diabetes. 30867485 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE Therefore, natural PPARγ targeting ligands are desirable alternatives for the management of insulin resistance associated with type 2 diabetes. 31279631 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 GeneticVariation disease GWASCAT Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. 31118516 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 AlteredExpression disease BEFREE These results suggest that the combined regulation of PPARγ, SMAD and the adrenergic receptor signalling pathway synergistically induces brown adipogenesis and may serve as an effective strategy to treat obesity and related diseases, including type 2 diabetes. 31317231 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE Synthetic PPARγagonists (thiazolidinediones or glitazones) have been used clinically in the treatment of type II diabetes. 31159430 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE This review would focus on the role of PPARs in the management of T2D; recently reported TZD derivatives which acted as agonists of PPAR- γ and its subtypes and are potentially useful in the new drug discovery for the disease. 31333088 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes. 31253533 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE Peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, pioglitazone, is used clinically to improve the glycemic state in patients with type-2 diabetes mellitus. 31730865 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 GeneticVariation disease GWASCAT Leveraging Polygenic Functional Enrichment to Improve GWAS Power. 30595370 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE Treatment with the insulin sensitizer PPARγ agonist rosiglitazone in patients with T2DM and CAD is associated with a worsening in aerobic exercise capacity, which seems to be mainly attributable to weight gain and subcutaneous fat mass expansion. 30964707 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 AlteredExpression disease BEFREE The effects of PPARγ agonists, known for their positive activity on type II diabetes mellitus, have been explored and present promising effects in the control of neuropathic pain, including CINP, and also cancer. 31555078 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 Biomarker disease BEFREE Pioglitazone (Pio) is a Food and Drug Administration-approved drug for type-2 diabetes that binds and activates the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ), yet it remains unclear how in vivo Pio metabolites affect PPARγ structure and function. 30676741 2019
Diabetes Mellitus, Non-Insulin-Dependent
0.700 GeneticVariation disease BEFREE The protective mechanisms of peroxisome proliferator-activated receptor gamma (PPARγ) Pro12Ala polymorphism in type 2 diabetes (T2D) are unclear. 30064293 2018
Diabetes Mellitus, Non-Insulin-Dependent
0.700 GeneticVariation disease BEFREE The pharmacological activators of PPARγ include thiazolidinediones (TZDs), which are insulin sensitizers used in the treatment of type 2 diabetes mellitus (T2DM), despite some drawbacks. 30060458 2018